The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model
Open Access
- 24 June 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 26 (9) , 2344-2352
Abstract
Endometriosis is still a highly underdiagnosed disease, and the current medical and surgical treatment of endometriosis is associated with a high recurrence rate. This study investigates the use of derivatives of the human antibody F8, specific to the alternatively spliced extra-domain A of fibronectin (Fn), for the imaging and treatment of endometriosis. Immunohistochemistry and immunofluorescence was used to evaluate antigen expression in endometriotic tissue of human endometriosis and of a syngeneic mouse model of the disease. The in vivo targeting performance of a fluorescent derivative of the F8 antibody was assessed by imaging mice with endometriosis using a near-infrared fluorescence imager, 24 h following i.v. injection of the antibody conjugate. Furthermore, the mouse model was used for therapy experiments using two recombinant F8-based immunocytokines [F8-interleukin-10 (IL10) and F8-IL2] or saline for the treatment groups. A very strong vascular expression of splice isoforms of Fn and of tenascin-C was observed in human endometriotic lesions by immunohistochemistry and immunofluorescence techniques. After i.v. administration, a selective accumulation of the F8 antibody in endometriotic lesions could be observed in a syngeneic mouse model. These targeting data were used as a basis for therapy experiments with a pro-inflammatory (F8-IL2) and an anti-inflammatory (F8-IL10) cytokine fusion protein of the F8 antibody. The average lesion size in the F8-IL10 treatment group was clearly reduced compared with the saline control group and with the F8-IL2 group, for which no therapeutic effects were observed. The F8 antibody targets endometriotic lesions in vivo in a mouse model of endometriosis and may be used for the non-invasive imaging of the disease and for the pharmacodelivery of anti-inflammatory cytokines, such as IL10.Keywords
This publication has 56 references indexed in Scilit:
- Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastomaBritish Journal of Cancer, 2010
- Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodiesAtherosclerosis, 2010
- Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritisArthritis Research & Therapy, 2009
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2Blood, 2009
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Tumour vascular targetingNature Reviews Cancer, 2005
- Diagnostic delay in women with pain and endometriosisActa Obstetricia et Gynecologica Scandinavica, 2003
- Molecular imaging in drug discovery and developmentNature Reviews Drug Discovery, 2003
- Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectinInternational Journal of Cancer, 2002
- TRANSMITTANCE OF NONIONIZING RADIATION IN HUMAN TISSUES*Photochemistry and Photobiology, 1981